Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon E. Bollag, Peter Hirth, James Y. Tsai et al. · Nature · 2010
Cited by 1,831 works. doi:10.1038/nature09454
Authors
- Gideon E. Bollag
- Peter Hirth
- James Y. Tsai
- Prabha N. Ibrahim
- Wayne R. Spevak
- Chao Zhang
- Ying Zhang
- Gaston G. M. Habets
- Bernice Huimin Wong
- Garson Tsang
- Brian L. West
- Ben Powell
- Rafe Shellooe
- Adhirai Marimuthu
- Hoa Trong Nguyen
- Kam Y. J. Zhang
- Dean R. Artis
References
- Mutations of the BRAF gene in human cancer
- Patterns of somatic mutation in human cancer genomes
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- BRAF mutation predicts sensitivity to MEK inhibition
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- High frequency of BRAF mutations in nevi
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- BRAFE600-associated senescence-like cell cycle arrest of human naevi
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth